Eris Lifesciences is set to fully acquire its injectable unit, Swiss Parenterals. The deal involves a share swap valued at Rs 423.3 crore. This move aims to enhance operational control and financial integration. Swiss Parenterals, a significant exporter, has shown consistent revenue growth. Eris also reported strong Q2 performance with increased revenue and profit.
Eris Lifesciences shares in focus on move to acquire Swiss Parenterals in Rs 423 crore deal
📅 Published: November 25, 2025 |
📂 Category: Uncategorized